Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
1.75 (USD) • At close September 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 67.425 | 0 | 0 | 0 | 0 | 0 | 0.014 |
| Cost of Revenue
| 1.289 | 1.389 | 1.426 | 0.544 | 0.16 | 0.111 | 0 |
| Gross Profit
| 67.425 | -1.389 | -1.426 | -0.544 | -0.16 | -0.111 | 0.014 |
| Gross Profit Ratio
| 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 167.768 | 189.59 | 172.734 | 175.601 | 84.901 | 38.386 | 18.921 |
| General & Administrative Expenses
| 87.115 | 59.398 | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 87.115 | 59.398 | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
| Other Expenses
| 3.736 | 3.564 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 258.619 | 252.552 | 227.287 | 216.542 | 118.787 | 46.845 | 23.797 |
| Operating Income
| -191.194 | -253.941 | -227.287 | -216.542 | -118.787 | -46.845 | -23.783 |
| Operating Income Ratio
| -2.836 | 0 | 0 | 0 | 0 | 0 | -1,698.786 |
| Total Other Income Expenses Net
| 25.504 | -38.965 | 5.987 | 50.152 | 0.683 | 0.482 | 0.355 |
| Income Before Tax
| -165.69 | -292.906 | -221.3 | -164.559 | -118.104 | -46.363 | -23.428 |
| Income Before Tax Ratio
| -2.457 | 0 | 0 | 0 | 0 | 0 | -1,673.429 |
| Income Tax Expense
| 0.177 | -0.601 | -0.469 | -0.297 | 0.444 | 0.015 | 0.004 |
| Net Income
| -165.839 | -292.191 | -236.806 | -158.725 | -117.841 | -46.378 | -21.067 |
| Net Income Ratio
| -2.46 | 0 | 0 | 0 | 0 | 0 | -1,504.786 |
| EPS
| -2.33 | -4.47 | -4.48 | -3.72 | -2.87 | -1.29 | -1.17 |
| EPS Diluted
| -2.33 | -4.47 | -4.48 | -3.72 | -2.87 | -1.29 | -1.17 |
| EBITDA
| -186.169 | -275.503 | -219.874 | -164.015 | -117.944 | -46.734 | -23.732 |
| EBITDA Ratio
| -2.761 | 0 | 0 | 0 | 0 | 0 | -1,695.143 |